Prostate cancer regulatory networks

Journal of Cellular Biochemistry

Volumn 107, Issue 5, 2009, Pages 845-852

  Altieri, Dario C ^a   Languino, Lucia R ^a   Lian, Jane B ^a   Stein, Janet L ^a   Leav, Irwin ^a   Van Wijnen, Andre J ^a   Jiang, Zhong ^a   Stein, Gary S ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Integrins; Prostate cancer; Regulatory networks; Runx; Signaling; Survivin

Indexed keywords

CD51 ANTIGEN; CHAPERONE; HEAT SHOCK PROTEIN 90; INTEGRIN; SURVIVIN; TRANSCRIPTION FACTOR RUNX2;

ADVANCED CANCER; CARCINOGENESIS; CELL COMMUNICATION; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; HOMEOSTASIS; HUMAN; MOLECULAR MODEL; MOLECULAR THERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

DRUG DISCOVERY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; INTEGRIN ALPHAV; MALE; MITOCHONDRIA; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 67749108155     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22162     Document Type: Review

References (123)

1. Akalu A, Cretu A, Brooks PC. 2005. Targeting integrins for the control of tumour angiogenesis. Expert Opin Investig Drugs 14:1475-1486.
2. Alam N, Goel HL, Zarif MJ, Butterfield JE, Perkins HM, Sansoucy BG, Sawyer TK, Languino LR. 2007. The integrin-growth factor receptor duet. J Cell Physiol 213:649-653.
3. Altieri DC. 2008. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8:61-70.
4. Araujo RP, Liotta LA. 2006. A control theoretic paradigm for cell signaling networks: A simple complexity for a sensitive robustness. Curr Opin Chem Biol 10:81-87.
5. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J, Molkentin JD. 2005. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434:658-662.
6. Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkentin JD. 2007. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat Cell Biol 9:550-555.
7. Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, Stein GS, Gerstenfeld LC. 2004. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases associated osteolytic disease. Cancer Res 64:4506-4513.
8. Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Wallace LA, Yingling JM, Lahn M, Arteaga C, Carducci M. 2008. TGF-beta signalling-related markers in cancer patients with bone metastasis. Biomarkers 13:217-236.
9. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. 2003. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33: 28-37.
10. Bernier J, Hall EJ, Giaccia A. 2004. Radiation oncology: A century of achievements. Nat Rev Cancer 4:737-747.
11. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. 2008. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 26:242-245.
12. Bisanz K, Yu J, Edlund M, Spohn B, Hung MC, Chung LW, Hsieh CL. 2005. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 12:634-643.
13. Blyth K, Terry A, Mackay N, Vaillant F, Bell M, Cameron ER, Neil JC, Stewart M. 2001. Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 20:295-302.
14. Brubaker KD, Vessella RL, Brown LG, Corey E. 2003. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 56:13-22.
15. Brubaker KD, Corey E, Brown LG, Vessella RL. 2004. Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 91:151-160.
16. Buijs JT, Henriquez NV, van Overveld PG, van der HG, ten Dijke P, van der PG. 2007. TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis 24:609-617.
17. Butcher EC. 2005. Can cell systems biology rescue drug discovery? Nat Rev Drug Discov 4:461-467.
18. Carter HB. 2006. Assessing risk: Does this patient have prostate cancer? J Natl Cancer Inst 98:506-507.
19. Cereceda LE, Flechon A, Droz JP. 2003. Management of vertebral metastases in prostate cancer: A retrospective analysis in 119 patients. Clin Prostate Cancer 2:34-40.
20. Chabner BA, Roberts TG, Jr. 2005. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 5:65-72.
21. Chang SF, Chang CA, Lee DY, Lee PL, Yeh YM, Yeh CR, Cheng CK, Chien S, Chiu JJ. 2008. Tumor cell cycle arrest induced by shear stress: Roles of integrins and Smad. Proc Natl Acad Sci USA 105:3927-3932.
22. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. 2004. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39.
23. Citri A, Yarden Y. 2006. EGF-ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol 7:505-516.
24. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. 2005. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
25. Cory S, Adams JM. 2002. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2:647-656.
26. Crompton M, Virji S, Doyle V, Johnson N, Ward JM. 1999. The mitochondrial permeability transition pore. Biochem Soc Symp 66:167-179.
27. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. 1994. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478.
28. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS, Keller ET. 2004. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 64:994-999.
29. Dairkee SH, Ji Y, Ben Y, Moore DH, Meng Z, Jeffrey SS. 2004. A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics 5:47.
30. Deininger M, Buchdunger E, Druker BJ. 2005. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640-2653.
31. Demetriou MC, Cress AE. 2004. Integrin clipping: A novel adhesion switch? J Cell Biochem 91:26-35.
32. Deng J, Carlson N, Takeyama K, Dal CP, Shipp M, Letai A. 2007. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12:171-185.
33. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. 2004. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114: 1117-1127.
34. Dohi T, Xia F, Altieri DC. 2007. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell 27:17-28.
35. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, de Koning HJ. 2003. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95:868-878.
36. Drews J. 2006. Case histories, magic bullets and the state of drug discovery. Nat Rev Drug Discov 5:635-640.
37. Eckelman BP, Salvesen GS, Scott FL. 2006. Human inhibitor of apoptosis proteins: Why XIAP is the black sheep of the family. EMBO Rep 7:988-994.
38. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG. 2004. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 6:507-514.
39. Felding-Habermann B. 2003. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 20:203-213.
40. Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB, Toft DO. 2000. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem 275:3305-3312.
41. Ferri KF, Kroemer G. 2001. Organelle-specific initiation of cell death pathways. Nat Cell Biol 3:E255-E263.
42. Fesik SW. 2005. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5:876-885.
43. FitzGerald TJ, Wang T, Goel HL, Huang J, Stein G, Lian J, Davis RJ, Doxsey S, Balaji KC, Aronowitz J, Languino LR. 2008. Prostate carcinoma and radiation therapy: Therapeutic treatment resistance and strategies for targeted therapeutic intervention. Expert Rev Anticancer Ther 8:967-974.
44. Fornaro M, Manes T, Languino LR. 2001. Integrins and prostate cancer metastases. Cancer Metastasis Rev 20:321-331.
45. Foster LJ, de Hoog CL, Zhang Y, Zhang Y, Xie X, Mootha VK, Mann M. 2006. A mammalian organelle map by protein correlation profiling. Cell 125:187-199.
46. Goel HL, Li J, Kogan S, Languino LR. 2008. Integrins in prostate cancer progression. Endocr Relat Cancer 15:657-664.
47. Green DR, Kroemer G. 2004. The pathophysiology of mitochondrial cell death. Science 305:626-629.
48. Guillemard V, Saragovi HU. 2004. Novel approaches for targeted cancer therapy. Curr Cancer Drug Targets 4:313-326.
49. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM. 2006. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12:6213s-6216s.
50. Gyurkocza B, Plescia J, Raskett CM, Garlick DS, Lowry PA, Carter BZ, Andreeff M, Meli M, Colombo G, Altieri DC. 2006. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst 98:1068-1077.
51. Hall CL, Dai J, van Golen KL, Keller ET, Long MW. 2006. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 66:8648-8654.
52. He L, Lemasters JJ. 2002. Regulated and unregulated mitochondrial permeability transition pores: A new paradigm of pore structure and function? FEBS Lett 512:1-7.
53. He L, Lemasters JJ. 2003. Heat shock suppresses the permeability transition in rat liver mitochondria. J Biol Chem 278:16755-16760.
54. Hengartner MO. 2000. The biochemistry of apoptosis. Nature 407:770-776.
55. Hua G, Zhang Q, Fan Z. 2007. Heat shock protein 75 (TRAP1) antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis. J Biol Chem 282:20553-20560.
56. Hynes RO. 2002. Integrins: Bidirectional, allosteric signaling machines. Cell 110:673-687.
57. Inman CK, Shore P. 2003. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 278:48684-48689.
58. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB, Stein GS. 2005. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 102:1454-1459.
59. Johnstone RW, Ruefli AA, Lowe SW. 2002. Apoptosis: A link between cancer genetics and chemotherapy. Cell 108:153-164.
60. Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, Altieri DC. 2007. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 131:257-270.
61. Karadag A, Ogbureke KU, Fedarko NS, Fisher LW. 2004. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 96:956-965.
62. Keller ET, Brown J. 2004. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91:718-729.
63. King TE, Pawar SC, Majuta L, Sroka IC, Wynn D, Demetriou MC, Nagle RB, Porreca F, Cress AE. 2008. The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS ONE 3:e3535.
64. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. 2007. Molecular biology of bone metastasis. Mol Cancer Ther 6:2609-2617.
65. Kitano H. 2003. Cancer robustness: Tumour tactics. Nature 426:125.
66. Knox JD, Cress AE, Clark V, Manriquez L, Affinito KS, Dalkin BL, Nagle RB. 1994. Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. Am J Pathol 145:167-174.
67. Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, MacGregor GR, Wallace DC. 2004. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 427:461-465.
68. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M. 2006. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375-388.
69. Kroemer G, Reed JC. 2000. Mitochondrial control of cell death. Nat Med 6:513-519.
70. Lamb J. 2007. The Connectivity Map: A new tool for biomedical research. Nat Rev Cancer 7:54-60.
71. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. 2006. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929-1935.
72. Li X, Placencio V, Iturregui JM, Uwamariya C, Sharif-Afshar AR, Koyama T, Hayward SW, Bhowmick NA. 2008a. Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene 27:7118-7130.
73. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM. 2008b. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27:596-603.
74. Lian JB, Javed A, Zaidi SK, Lengner C, Montecino M, van Wijnen AJ, Stein JL, Stein GS. 2004. Regulatory controls for osteoblast growth and differentiation: Role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 14:1-41.
75. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. 2005. Pathogenesis and treatment of prostate cancer bone metastases: Targeting the lethal phenotype. J Clin Oncol 23:8232-8241.
76. Masuda Y, Shima G, Aiuchi T, Horie M, Hori K, Nakajo S, Kajimoto S, Shibayama-Imazu T, Nakaya K. 2004. Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin. J Biol Chem 279:42503-42515.
77. McCabe NP, De S, Vasanji A, Brainard J, Byzova TV. 2007. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene 26:6238-6243.
78. Meli M, Pennati M, Curto M, Daidone MG, Plescia J, Toba S, Altieri DC, Zaffaroni N, Colombo G. 2006. Small-molecule targeting of heat shock protein 90 chaperone function: Rational identification of a new anticancer lead. J Med Chem 49:7721-7730.
79. Mundy GR. 2002. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593.
80. Munshi HG, Stack MS. 2006. Reciprocal interactions between adhesion receptor signaling and MMP regulation. Cancer Metastasis Rev 25:45-56.
81. Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ. 1997. Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 33:263-271.
82. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T, Tsujimoto Y. 2005. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434:652-658.
83. Nguyen DX, Massague J. 2007. Genetic determinants of cancer metastasis. Nat Rev Genet 8:341-352.
84. O'Dwyer ME, Druker BJ. 2000. ST I571: An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol 1:207-211.
85. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681.
86. Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, Margue C, Cohen-Solal M, Buffet A, Kieffer N, Clezardin P. 2002. Integrin alpha(v)-beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 16:1266-1268.
87. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. 2000. Molecular portraits of human breast tumours. Nature 406:747-752.
88. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, Gabrilovich DI, Colombo G, Altieri DC. 2005. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7: 457-468.
89. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2005. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25:8581-8591.
90. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS. 2006. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 25:589-600.
91. Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2008. Runx2 transcriptional activation of Indian hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 68:7795-7802.
92. Pridgeon JW, Olzmann JA, Chin LS, Li L. 2007. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 5:e172.
93. Rajasethupathy P, Vayttaden SJ, Bhalla US. 2005. Systems modeling: A pathway to drug discovery. Curr Opin Chem Biol 9:400-406.
94. Roodman GD. 2004. Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664.
95. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. 2008. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 180:1154-1160.
96. Sawyers C. 2004. Targeted cancer therapy. Nature 432:294-297.
97. Schein PS, Scheffler B. 2006. Barriers to efficient development of cancer therapeutics. Clin Cancer Res 12:3243-3248.
98. Schinzel AC, Takeuchi O, Huang Z, Fisher JK, Zhou Z, Rubens J, Hetz C, Danial NN, Moskowitz MA, Korsmeyer SJ. 2005. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci USA 102:12005-12010.
99. Selvamurugan N, Kwok S, Partridge NC. 2004. Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells. J Biol Chem 279:27764-27773.
100. Sharma SV, Bell DW, Settleman J, Haber DA. 2007. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169-181.
101. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274.
102. Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW, Foekens JA. 2006. Genes associated with breast cancer metastatic to bone. J Clin Oncol 24:2261-2267.
103. Stein WD, Bates SE, Fojo T. 2004. Intractable cancers: The many faces of multidrug resistance and the many targets it presents for therapeutic attack. Curr Drug Targets 5:333-346.
104. Strausberg RL, Simpson AJ, Old LJ, Riggins GJ. 2004. Oncogenomics and the development of new cancer therapies. Nature 429:469-474.
105. Sun L, Vitolo M, Passaniti A. 2001. Runt-related gene 2 in endothelial cells: Inducible expression and specific regulation of cell migration and invasion. Cancer Res 61:4994-5001.
106. Taichman RS, Loberg RD, Mehra R, Pienta KJ. 2007. The evolving biology and treatment of prostate cancer. J Clin Invest 117:2351-2361.
107. Vaillant F, Blyth K, Terry A, Bell M, Cameron ER, Neil J, Stewart M. 1999. A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with MYC. Oncogene 18:7124-7134.
108. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. 2002. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009.
109. van der Greef J, McBurney RN. 2005. Innovation: Rescuing drug discovery: In vivo systems pathology and systems pharmacology. Nat Rev Drug Discov 4:961-967.
110. Verma M, Kagan J, Sidransky D, Srivastava S. 2003. Proteomic analysis of cancer-cell mitochondria. Nat Rev Cancer 3:789-795.
111. Vogelstein B, Kinzler KW. 2004. Cancer genes and the pathways they control. Nat Med 10:789-799.
112. Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, Trikha M, Nemeth JA, Zaki MH, Keller ET. 2006. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgendependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 66:3087-3095.
113. Waltregny D, Bellahcene A, de L X, Florkin B, Weidle U, Castronovo V. 2000. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 15:834-843.
114. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. 2001. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 292:727-730.
115. Weinstein IB, Joe AK. 2006. Mechanisms of disease: Oncogene addiction-A rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3:448-457.
116. Whitesell L, Lindquist SL. 2005. HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761-772.
117. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. 2007. The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113.
118. Woodfield K, Ruck A, Brdiczka D, Halestrap AP. 1998. Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition. Biochem J 336(Pt 2): 287-290.
119. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM. 2001. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 61:5652-5659.
120. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. 2004. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927-939.
121. Zamzami N, Kroemer G. 2001. The mitochondrion in apoptosis: How Pandora's box opens. Nat Rev Mol Cell Biol 2:67-71.
122. Zayzafoon M, Abdulkadir SA, McDonald JM. 2004. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem 279:3662-3670.
123. Zhang JH, Tang J, Wang J, Ma W, Zheng W, Yoneda T, Chen J. 2003. Over-expression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model. Int J Oncol 23:1043-1048.